Table 5.

Sensitivity Analyses on the risk of VTE in patients with Giant Cell Arteritis

	Primary Analysis(N= 909) HR (95%CI)	Sensitivity Analysis 1(N= 909) HR (95%CI)	Sensitivity Analysis 2(N= 593) HR (95%CI)	Sensitivity Analysis 3(N= 909) HR (95%CI)

				Prevalence = 10%^a OR^b = 1.3	Prevalence = 10% ^a OR^b = 3.0	Prevalence = 20% ^a OR^b = 1.3	Prevalence = 20% ^a OR^b = 3.0
VTE	2.49 (1.45–4.30)	2.15 (1.29–3.56)	2.43 (1.33–4.43)	2.44 (1.41–4.19)	2.05 (1.20–3.52)	2.49 (1.44–4.29)	1.88 (1.07–3.28)
PE	2.71 (1.32–5.56)	2.34 (1.15–4.76)	2.48 (1.11–5.52)	2.61 (1.27–5.37)	2.15 (1.05–4.38)	2.65 (1.29–5.45)	1.89 (0.90–3.96)
DVT	2.78 (1.39–5.54)	2.30 (1.25 (4.22)	2.88 (1.35–6.16)	2.68 (1.34–5.34)	2.38 (1.20–4.70)	2.87 (1.43–5.77)	2.13 (1.05–4.33)

DVT, Deep vein thrombosis; HR, Hazard ratio; OR, Odds ratio; PE, Pulmonary embolism; VTE, Venous thromboembolism

hypothetical prevalence of the unmeasured confounder in the giant cell arteritis cases

hypothetical level of association between the unmeasured confounder and the outcome

Sensitivity analyses 1; accounting for the competing risk of death

Sensitivity analyses 2; limited to giant cell arteritis cases that received at least 5 prescriptions for oral glucocorticoids during follow-up

Sensitivity analyses 3; accounting for unmeasured confounders